Bal Pharma's Q1 FY 2025-26 Quarterly Results
- 12 Aug 2025
Result Summary
- Bal Pharma Ltd reported a 31.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 11.4%.
- Its expenses for the quarter were down by 27.3% QoQ and 11.0% YoY.
- The net profit decreased 96.2% QoQ and decreased 19.2% YoY.
- The earnings per share (EPS) of Bal Pharma Ltd stood at 0.1 during Q1 FY 2025-26.
Financial Statments for Q1 FY 2025-26
Total Income | 66.59 | 97.08 | 75.18 | -31.4% | -11.4% |
Total Expenses | 66.38 | 91.33 | 74.56 | -27.3% | -11.0% |
Profit Before Tax | 0.21 | 5.75 | 0.62 | -96.3% | -66.1% |
Tax | 0.00 | 0.22 | 0.36 | -100.0% | -100.0% |
Profit After Tax | 0.21 | 5.53 | 0.26 | -96.2% | -19.2% |
Earnings Per Share | 0.10 | 3.70 | 0.20 | -97.3% | -50.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Bal Pharma Ltd is a pharmaceutical company that primarily operates in the healthcare sector, focusing on the development, manufacturing, and marketing of pharmaceutical products. The company's portfolio includes a variety of formulations and active pharmaceutical ingredients (APIs) covering several therapeutic categories. These categories often include cardiovascular, anti-diabetic, gastrointestinal, and anti-infective segments, among others. The company serves both domestic and international markets, leveraging its research and development capabilities to introduce new products. Recent major developments or specific product launches for Bal Pharma Ltd are not available from the provided data, and further detailed insights into its strategic initiatives or market position would require additional information beyond the financial figures given.
Revenue
In the first quarter of the fiscal year 2026 (Q1FY26), Bal Pharma Ltd reported a total income of ₹66.59 crore. This represents a decrease of 31.4% from the previous quarter (Q4FY25), where the total income was ₹97.08 crore. On a year-over-year basis, comparing Q1FY26 to the first quarter of the previous fiscal year 2025 (Q1FY25), there is a decline of 11.4% from ₹75.18 crore. These figures highlight a reduction in revenue both sequentially and annually, indicating changes in the company's sales performance over the periods in question.
Profitability
For Q1FY26, Bal Pharma Ltd's profit before tax stood at ₹0.21 crore, showing a significant decrease of 96.3% from ₹5.75 crore in the previous quarter (Q4FY25). Compared to the same quarter in the previous year (Q1FY25), this represents a 66.1% decrease from ₹0.62 crore. The tax expense for Q1FY26 was reported as zero, leading to a profit after tax of ₹0.21 crore. This reflects a decrease of 96.2% from the previous quarter's profit after tax of ₹5.53 crore and a 19.2% decrease year-over-year from ₹0.26 crore. Earnings per share (EPS) in Q1FY26 were ₹0.10, down 97.3% from ₹3.70 in Q4FY25, and a 50.0% decline from ₹0.20 in Q1FY25. The reductions in profitability metrics suggest challenges in maintaining earnings levels during the quarter.
Operating Metrics
Bal Pharma Ltd's total expenses for Q1FY26 were reported at ₹66.38 crore, marking a 27.3% decrease from ₹91.33 crore in Q4FY25. Year-over-year, this represents an 11.0% reduction from ₹74.56 crore in Q1FY25. The decrease in expenses quarter-over-quarter and year-over-year aligns with the overall decline in income, reflecting adjustments in the company’s operating cost structure. The substantial reduction in tax expense to zero for Q1FY26 compared to Q4FY25 and Q1FY25 contributes to the change in net profitability. While specific operating metrics such as P/E ratio, debt-to-equity ratio, or current ratio are not provided in the data, the financial performance outlined focuses on income and expenses as key drivers of operational outcomes.